# Xeris Biopharma Holdings, Inc. (XERS) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from Xeris Biopharma Holdings, Inc.'s 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/XERS/mda/fy2025/): filed 2026-03-02; accession 0001867096-26-000016 (https://www.sec.gov/Archives/edgar/data/1867096/000186709626000016/xers-20251231.htm); latest 10-K
- [FY 2024 MD&A](/company/XERS/mda/fy2024/): filed 2025-03-06; accession 0001867096-25-000039 (https://www.sec.gov/Archives/edgar/data/1867096/000186709625000039/xers-20241231.htm)
- [FY 2023 MD&A](/company/XERS/mda/fy2023/): filed 2024-03-06; accession 0001867096-24-000031 (https://www.sec.gov/Archives/edgar/data/1867096/000186709624000031/xers-20231231.htm)
- [FY 2022 MD&A](/company/XERS/mda/fy2022/): filed 2023-03-08; accession 0001867096-23-000031 (https://www.sec.gov/Archives/edgar/data/1867096/000186709623000031/xers-20221231.htm)
- [FY 2021 MD&A](/company/XERS/mda/fy2021/): filed 2022-03-11; accession 0001867096-22-000040 (https://www.sec.gov/Archives/edgar/data/1867096/000186709622000040/xers-20211231.htm)

Back to /company/XERS/